About the Company

Those who want to protect their health over the long term should not wait until something goes wrong before taking action. That belief is at the heart of why we founded AYUN.

At our longevity and preventive medicine clinic in Zurich, we combine comprehensive medical diagnostics with personalized interventions and measurable follow-ups. Rather than looking at individual health metrics in isolation, our physicians and specialists bring together multiple dimensions of health to develop a personalized strategy. Our goal is to empower people to take an active role in their health and stay healthy for as long as possible.

• Proven demand: 1,500 clients have already chosen AYUN, generating CHF 2.7 million in revenue since launch.

• Measurable health outcomes: 60% retest rate; 7 out of 10 check-up clients who completed a retest achieved measurable improvements in their health.

• High client satisfaction: A Net Promoter Score of 77 reflects strong client satisfaction and willingness to recommend AYUN.

• Referrals as a key growth driver: 40% of new clients come to AYUN through personal recommendations.

• Attractive unit economics: A 75% gross margin on check-ups and already profitable customer acquisition provide a strong foundation for further growth.

• Proprietary technology platform: The Clinical Engine and AYUN Health Score connect health data, personalized recommendations, and digital progress tracking.

Benefits for Co-Owners and Investors

Invest in the Future of Healthcare

We are looking for investors who share our belief: the future of medicine is not only about better treatment, but also about understanding health earlier and taking a more proactive approach. As a co-owner of AYUN, investors can participate in:

• An established foundation: AYUN is an operating business with an established clinic, team, and technology platform. Since launch, 1,500 clients have generated CHF 2.7 million in revenue, demonstrating existing demand.

• Attractive unit economics: A 75% gross margin on check-ups and customer acquisition that is already profitable from the first check-up provide a strong foundation for profitable growth. In addition, 40% of new clients come through personal referrals.

• Recurring clients and revenue: 60% of clients return for another check-up within one year, demonstrating the potential for recurring revenue and increasing customer lifetime value.

• Multiple avenues for growth: Investors participate in the continued expansion of the Zurich clinic as well as AYUN’s plans to open additional locations.

• Scalable proprietary technology: With the Clinical Engine and AYUN Health Score, AYUN has built a proprietary technology platform designed to scale beyond individual clinic locations and enable new business models.

• A strong investor network: Investors join experienced business angels, investors, and longevity company builder Maximon, becoming part of a network that brings together capital, experience, and entrepreneurial expertise.

• An investment investors can experience firsthand: Investors can use AYUN’s services themselves while participating as co-owners in the company’s continued development.

• Long-term value creation potential: By scaling AYUN, the company aims to sustainably increase enterprise value and create additional strategic opportunities over the long term.

Milestones

2022

• AYUN founded with the vision of redefining preventive and longevity medicine

• Maximon and the Longevity Co-Investment Fund join as investors

2023

• Development of AYUN’s medical concept together with scientists and physicians

• Search for and selection of the first clinic location in Zurich

• Preparation of an integrated offering combining diagnostics, therapies, and coaching

2024

• Opening of the AYUN clinic in Zurich in July

• Launch of personalized check-ups and therapies

• Launch of AYUN’s proprietary technology platform

• Introduction of the AYUN Health Score to measure health status and progress

• Acquisition of the first paying clients

2025

• Pioneering Women’s Health: launch of the Women’s Health Program, bringing a female-specific approach to prevention and longevity

• Expansion of the medical offering for women, including dedicated programs for menopause and fertility, as well as support for PCOS and endometriosis

• Expansion of the medical team and gynecological expertise

• Increased media visibility through coverage on Swiss television and in leading publications

2026

• First months of positive EBITDA achieved

• Expanded collaboration with supplementary health insurers, with additional insurers and broader reimbursement for selected AYUN services

• Recognition by basic health insurance, with preparations underway for the reimbursement of selected medical services

• Launch of AYUN 360 for medical tourism and acquisition of the first clients

• Entry into Corporate Health with the acquisition of AYUN’s first corporate clients

Testimonials

“After many years in clinical psychiatry, I know how important it is to focus on health before symptoms arise. AYUN’s preventive approach and commitment to looking at health holistically are therefore particularly relevant to me.”

KD Dr. med. Janis Brakowski, Specialist in Psychiatry, Psychotherapy & Longevity

“I invest in companies that deliver results. With AYUN, I see that progress not only as an investor — I experience it personally as well.”

Dr. Tobias Reichmuth,  Entrepreneur & Longevity Investor

“Longevity is a market with enormous potential. But I’m not only an investor in AYUN — I’m also a client. And there’s a reason for that.”

Marc P. Bernegger, Entrepreneur & Longevity Investor

“As an athlete, I rely on clarity, precision and measurable results to perform at my best. AYUN turned complex health data into clear, actionable insights that have directly shaped my nutrition, training and recovery.

As an example, the combination of longevity-focused blood biomarkers and genetic analysis gave me personalised guidance that removed the guesswork from supplementation – and even helped optimise my spending. For me, AYUN transforms health data into better decisions, better performance, and a more proactive approach to long-term health.”

Nick Lau, Cross-Country Skier & Hybrid Athlete

Our Vision - Why invest in AYUN ?

Our vision is to build AYUN into a leading company in preventive and longevity medicine and one of the most trusted brands in proactive health. We want to empower people to take control of their health, with the goal of living longer, healthier, more active, and self-determined lives.

We believe personalized prevention should become an integral part of modern healthcare. To make this possible, we combine science-based diagnostics, medical expertise, and personalized guidance with our proprietary technology. This allows us to identify health risks earlier, translate insights into targeted action, and measure progress over time.

Our growth journey starts in Zurich. From this foundation, we aim to build an international network of clinics while continuing to scale our technology platform. This will enable us to make the AYUN approach accessible far beyond individual locations — with Swiss quality, precision, and trust as our benchmark.

By investing in AYUN, you become part of this next phase of growth and support the development of an internationally scalable company with a clear ambition: more healthy years for more people.

FAQ

Was macht AYUN genau?

AYUN is a longevity and preventive medicine clinic in Zurich. We combine comprehensive medical diagnostics with personalized interventions and follow-up testing to identify health risks early and measure changes over time.

Wie verdient AYUN Geld?

AYUN generates revenue from health check-ups, personalized treatments, and long-term health programs. Regular treatments and follow-up assessments create recurring revenue. In the future, our proprietary technology platform offers additional revenue potential.

Warum habt ihr euch für Crowdinvesting als Finanzierung entschieden?

Crowdfunding gives people who believe in our vision the opportunity to become co-owners of AYUN and participate in our journey. Beyond providing growth capital, our investors can become valuable ambassadors — recommending AYUN, introducing new clients, and opening doors to potential partners. This combination of ownership and advocacy can increase awareness, strengthen customer acquisition, and accelerate sustainable growth.

Warum ist jetzt der richtige Zeitpunkt zum Investieren?

With 1,500 clients and CHF 2.7 million in cumulative revenue, AYUN has already demonstrated demand for its business model. The first months of positive EBITDA further demonstrate its economic potential. This financing round takes place ahead of AYUN’s next phase of growth: scaling the Zurich clinic, further developing the technology platform, and expanding to additional locations.

Wie seid ihr auf die Firmenbewertung gekommen?

Based on projected 2026 revenue of CHF 1.4 million, a 5× revenue multiple implies a valuation of approximately CHF 7 million. Considering the expected increase in revenue to CHF 2.5 million in 2027, together with the additional potential of AYUN’s technology and AI platform, AYUN believes a pre-money valuation of CHF 12 million is well supported.

Was bekomme ich als Investor?

Investors gain an economic interest in AYUN and may participate in a potential increase in company value in the event of an exit. The exact investment structure, instrument, and terms are set out in the investor documentation.

Erhalte ich Stimmrecht?

Investments made through AYUN’s crowdfunding campaign do not carry voting rights. Investors will nevertheless remain closely connected to the company through regular updates on AYUN’s development and key milestones. AYUN also plans to hold an annual investor event where investors can meet the team, ask questions, and connect with other investors.

Erhalte ich Dividenden?

AYUN is currently focused on growth and long-term value creation. The intention is therefore to reinvest future profits in the continued development of the company. Dividend payments are not currently planned during this phase.

Ist ein Exit geplant?

AYUN’s primary objective is to build the company sustainably and increase its long-term value. Over time, potential liquidity options could include a strategic exit, secondary transactions, or an IPO. However, neither the timing nor the form of any such transaction has been determined.

Invest in the future of health — and be part of AYUN’s next phase of growth.